London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ray
I just presumed you were quoting the philosopher Friedrich Nietzsche.....
Chester.
Michael,
I enjoyed your post, valid points and presented well.
Your comment about academics sticking to research rather than being company executives can be argued two ways...
Yes, prof Durrant is an academic and produces many academic papers. It is a great disappointment to many that she refuses to join Scancell full time and continues in her dual role at Nottingham university.
On the other hand, much of the Result of research of Nottingham university has been acquired by Scancell.
In terms of PR, prof Durrant is the best executive we have - by a long chalk!
Hi Ray,
The science of most of the pharmas does go over the head of many investors you only need to be in a few to see that.
But what they do understand is delays and lack of SH communication which of is the job of the pharma to explain the science assuming they want/ need investors which obviously SCLP need.
One simple example which I would be happy for anyone to say is acceptable as I don’t think it is.
The Bion Tech/SCLP partnership was agreed on 9th Jan,2018. To my knowledge there has been no further SH communication on this matter or update as to whether it is still in place or what if any the outcome has been.
So does anyone think this is “ acceptable “ or do we just sit like the proverbial mushrooms until told otherwise.
'Yes, prof Durrant is an academic and produces many academic papers. It is a great disappointment to many that she refuses to join Scancell full time and continues in her dual role at Nottingham university.'
Not that rotten chestnut again!.... Did you not see via SKY scancell is a Notts Uni company the labs are there! Scancell gains hugely from it not least from getting staff...... Do not worry all Lindys work is scancells IP there is zero negative of her still holding her Notts Uni position she is working on her work scancells IP!!! ......
For me this year will be about CH getting us the first at least Avidimab/Glycan deal he is down as saying he expects it later in this yeat... though that was pre covid but still... So if we get that ball rolling scancell are then on the right track ... yes lots of other possibilities Covidity action moditope getting deals especially modi 1 the now trial-ready product and TCR potential .... sp pattern is predictable rises on positive news of potential money coming in and falls as that news fades one of these days one piece of scancells IP will nail a deal that is why I never bother rushing to buy on the good news and wait for as it is now to start nibbling again as the market loses interest.
Hi Ivy
The delay in the BionTech collaboration was explained at the last AGM.
It remains on presentation slides throughout, so you have to conclude it is ongoing.
It also appears that from recent posts by Inan that Lindy's team have come up with a patentable process as part of the end-to-end process of creating the viral vector. Just typical, she just has to find something new.
But I do get what you mean, work is ongoing on many projects and it would be nice to get an update on each of these at regular intervals.
The big delay in the SCIB1/Keytruda trial is the only delay I take issue with. Perhaps more could have been done to get the trial started earlier in the UK or anywhere outside the US.
But overall I stand by my statement that how the rest of the scientific community (maybe excluding Oxford Uni LOL) rate Lindy's science is the real litmus test. And the colour of the litmus paper is not changing IMO.
I wonder how much it costed to kit out that room full of electron microscopes.
More than any AIM investor would be willing to pay for a 'start-up' company no doubts.... what an asset it is having access to all that equipment.... apparently Lindy is only using it part-time... lol so for half a day she is in the lab in her notes white coat then in the afternoon the scancell logo white coat goes on
Crumbs,
You are of course entitled to your opinion. How do you explain David Evans statement that not getting Prof Durrant to go full time With Scancell as his biggest failure?
Let him explain that one to me his greatest failure is no SCIB1 deal.... but at least he got us SKY tv so we could see those Notts labs ... which I do not think scancell could afford to buy and maintain
Crumbs,
Touché. I’ll give you that one!
We can surely agree on my other point that Prof Durrant is Scancells best PR asset?
Possibly Evans meaning by that was he would rather Lindy spent more of her time pushing scancell the company... well to me that is the other BOD members jobs which they have failed to do yes she is the brightest asset but as I say all her IP is in scancell that IP she develops via Notts Uni..... turning that commercial well really is that down to her? they let that vulpes scientist into the labs did they not and he liked what he saw enough to recommend investment.... What we need is a Sean Marret of BioNTech... Sahin do the science Marret nail the deals and finance.
DE also bought a million shares at 7p not that long ago, so he's either got a financial death wish or he sees something promising. I would suspect the latter, although he is probably more of an investor than a trader, which may explain a lot here lately.
Absolutely agree with that and she may be reticent in giving her precious time to meeting pharmas in offices talking about business .... She does her bit though and her time is best spent on the science also probably since Evans time she might have become more involved in pushing scancell the company ... there have been times I've wondered does she even properly communicate with the rest of the BOD as in sometimes CH does not seem in the loop as in up to date with what is happening in the lab...... he didn't seem to know of the 6 months TCR delay for instance
Another advantage is that Lindy is a slave trader. The slaves being PhD students in Nottingham and indeed other Unis.
It is a fairtrade between her and the students lol.... gain gain...
Hi Ray,
Thanks for considered reply.
I could have picked other egs and the one you highlight is another very good case in point as we know this was first RNSd in December 2015 but equally there has been some feedback re the delays and I accept some of them but do agree with your sentiment.
There may have been some feedback on the Bion Tech eg at the AGM but again it would be nice to have it confirmed as ongoing and get some general update as what it has led to.
Snippets and speculation based on “ patentable processes” which we know just leads to more questions should imo be replaced by regular updates from SCLP which no one should have to interpret or try and 2nd guess.
Anyway sure we will get some news soon and agree Lindy is brilliant but the science us only half the story in any investment imo
To me this year CH gets to prove himself his background is MaBs I like the packaging of AvidiMab and Glycans and he has been successful in translating that into 3 collaborations with players possibly very impressive ones... now the final step the try before you buy resulting in real deal/s ones that may well surprise us with the £ attached ..... over to him of course you would expect if the techs are impressing.... the collaborators will want them and the deal should be a cakewalk for the dealmaker
Crumbs,
From memory, David Evans' point related to the expectations of potential investors in the Company. The large/specialist fund managers wanted and expected to see a CSO devoting 100% of her time to the Company they were being asked to invest in.
Of course, we'll never know what difference it made and as you say, LD's role at UoN does bring many advantages too.
Hopefully, the thinking around that is changing and the importance of academia connections is becoming more appreciated ....Anyways I think we are all in need of some form of update :)
Hello RuckRover
Re your 19.43 post of yesterday: first, thank you for the polite tone of your post. The comments in my post at the origin of this thread, were referring to the overall management style of SCLP and the whole of the management team and were by no means specific (only) to professor Durrant - I also take on board what you say about her re PR (of substance) and we can't deny the credit that is due to her re the IP credentials of Scancell and, very likely, in other respects too.
In the post, I asked a few questions and highlighted areas where SCLP is lacking, mainly in the operations arena. Hence the significant delays in projects, the disjointed RNSs that aren't followed up on time, the lack of sufficient commercial progress and adding to that the irregular investor updates ... is it a wonder the valuation is at comparable levels to that of a startup or even below? It is possibly telling that the company has a CEO and a CSO but not an obvious COO (chief operations officer) to make sure tasks get done across areas of responsibilities. If it is mainly the CEO that has taken over such role, then he needs to up his game. There are also 4 NEDs, possibly too many for the size of the company (i.e. many chiefs and not enough resources on the execution front).
Could it be that the responsibility for the operational tasks lies among the CEO, a part-time CSO and possibly the Development Director? If so, is it a surprise that project management and the execution of any follow-up tasks related issues related to timely progressing of trials, product development and other fronts (as we have seen in the past) appear to be very delayed or even falling between the cracks?
To summarise, the company certainly has credentials to demonstrate in the research arena, but it is the follow-up on those that matters in the commercial world. Creating and developing / perfecting valuable IP is essential, but ultimately, it's how you manage that IP that will determine success for a company. And yes, success is not only about the profit line, but it certainly is related to bringing benefits to all stakeholders (including first and foremost patients that might benefit from a final product). Maybe a few topics to raise at the next AGM?
Michael, I think you have assessed the company and mood of several investors very well.
As a startup, a company has a lot of optimism surrounding it and not a lot of negatives. It takes time to acquire negatives - results falling short of expectations, slipping timescales, withdrawal of significant investors, change of personnel, increased cash burn etc etc. I am talking about startups generally - Scancell have not suffered from all of the above, but certainly some.
It’s a bit like interviewing internal and external candidates for a job. You know all the weaknesses of the internal people but none of the external ones are going to point their’s out.
Inan, you asked “what good points”.....
I think the main one was engaging better and more broadly with the market. After all, it is the market that ultimately defines the value of the company (currently 5.35p)
So better communication to answer...
What’s the revised timetable for the SCIB1 combo trial?
What’s the revised timetable for the SCIB2 trial?
What’s the revised timetable for the MODI1 trial?
Any progress on MODI2?
Any news on the BioNTech collaboration?
Any news on funding?
What’s the revised timetable on getting some “great data”?
What is the revised timetable on “monetising assets”?
Any news on COVIDITY development?
Any news on COVIDITY funding?
didn't see those in his list Ruck
anyway you have a friend ... ATB
""That the negative posters can appreciate and who incites a little rebellion ""
how ever ... Micheal regards Lindy as "acting as an Academic"
considering he has been in the shares For "years" ..apparently ...
how on earth he can make that comment when the guy does NOT have a clue about the science of scancell ...
sometimes Ruck a little research into a party goes a long way to asses what wine they bring ...
Sour ... is not appreciated by the connoisseurs of the science or commercial businessmen in general
so its best you give him privilege over your shares so that he can stir it up at an AGM ...
i suspect he would need at least 80m to achieve any sort of influence
by the way he has put out this sort of nonsense before ...
"""""But I stick to the point that management and the Board should also put on a business hat from time to time in addition to acting like academics.""""
"""A few questions:
- what does DC stand for?
- if the approaches are similar, where do SCLP's competitive advantages lie (if any)? As importantly, are such competitive advantages protected by patents?
- got a bit lost with Inanaco's 16:07 post ... broadly speaking, is the idea to get the virus stuck on the surface of a cell and not let it go inside the cell to destroy it?
- oh, and are the HLA phenotypes the places on the cells where the virus binds to something? """"
anyway i will leave it at that ... I consider he is not up to the job of leading a "rebellion" ... time will tell
Cricket ...
lozan asks ... "what rebellion "
""""The aim of my post was to see to what extent other investors had similar thoughts about issues related to the overall management style in order to bring them up at the AGM in a concerted way. """"
posted Last Night ...
so lets see those that REC the post ... commit your shares to Micheal ...
should be interesting
inanaco you certainly have quite an opinion of yourself
the bb, as I understand it, is to inform and tease out issues. It seems a pity that you fervently dismiss views that are not your own!